Answers are grounded in this paper and cite their sources.
Study objectives To determine the effect of transvenous phrenic nerve stimulation (TPNS) on the composition of the nocturnal hypoxemic burden in patients with CSA. Methods We analysed oximetry data from baseline and follow-up overnight polysomnograms (PSG) in 134 CSA patients with implanted TPNS randomised (1:1) to neurostimulation (treatment group; TPNS on) or no stimulation (control group; TPNS off) from the remedē System Pivotal Trial. The hypoxemic burden was quantified using a battery of metrics, including the oxygen desaturation index (ODI), the relative sleep time spent below 90% SpO2 (T90) due to acute episodic desaturations (T90 desat ) and due to non-specific and non-cyclic drifts of SpO2 (T90 non-specific ). Mean change from baseline is provided. Results TPNS titrated to reduce respiratory events significantly reduced the ODI in the treatment group by −15.85 h −1 ± 1.99 compared to the control group, which increased 1.32 h −1 ± 1.85 ( p 〈0001) and shortened the relative T90 duration by −3.81 percentage points ± 1.23 vs. 0.49 percentage points ± 1.14 increase ( p = 0.012). This shortening of T90 was primarily accomplished by reducing the brief cyclic desaturations (T90 desaturation : −4.32 percentage points ± 0.98 vs. 0.52 percentage points ± 0.91, p = 0.0004) while notable non-specific drifts in SpO 2 remained unchanged (T90 non-specific : 0.18 percentage points ± 0.62 vs. -0.13 percentage points ± 0.57, p = 0.72). Conclusions TPNS appears to significantly reduce the nocturnal hypoxemic burden due to sleep-disordered breathing, but a considerable nocturnal hypoxemic burden from other sources remains. Further investigations are warranted to identify the best strategy to reduce the nocturnal hypoxemic burden beyond preventing respiratory events.
No takes yet. Share an insight, caveat, or question.
Baumert et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: